What question did this study set out to answer?

To develop and validate a liquid chromatography-mass spectrometric assay for direct oral anticoagulants to guide dosage adjustment.

April 2, 2014Therapeutic Drug Monitoring

Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry

View Full Paper

Ask AI

Bookmark

To develop and validate a liquid chromatography-mass spectrometric assay for direct oral anticoagulants to guide dosage adjustment.
Developed a liquid chromatography-mass spectrometric assay for apixaban, dabigatran, edoxaban, and rivaroxaban.
Analyzed samples using a TurboFlow column and high-resolution mass spectrometry.
Evaluated drug stability and calibration linearity across various conditions.
Intra-assay imprecision at 1 μg/L was 2.6% for apixaban, 4.2% for dabigatran, 17.3% for edoxaban, and 9.5% for rivaroxaban.
Mean recovery rates were between 96%-101%.
Edoxaban showed a deterioration of 16% after 2 weeks at 2-8°C and 70% at room temperature after 2 weeks.

Structured PICO

Population

Human plasma samples for measurement of direct oral anticoagulants

Intervention

Turbulent flow liquid chromatography with high-resolution mass spectrometry

Outcome

Assay performance characteristics including intra-assay imprecision, recovery, and stabilitysurrogate

A newly developed liquid chromatography-mass spectrometric assay provides a rapid and reliable method for therapeutic drug monitoring of direct oral anticoagulants in human plasma.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

May support LC-MS assay development for DOAC TDM; leaves open inter-assay reproducibility and clinical outcome validation.

Cite This Study

Gous et al. (2014) studied this question.

synapsesocial.com/papers/6a20745355fc9dbe7378052c https://doi.org/10.1097/ftd.0000000000000059

View Full Paper

Ask AI

Bookmark

Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry

Key Points

Structured PICO

Discussion

Implication

Cite This Study

Also Consider

Also Consider